New drug aims to boost insulin sensitivity and muscle health in diabetes

NCT ID NCT07137585

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This early-stage trial tests whether a drug called RO7204239 can improve how the body uses insulin and affects muscle composition in 30 adults with type 2 diabetes who are overweight or obese. Participants will receive either the drug or a placebo, and researchers will measure changes in insulin sensitivity and blood sugar control over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RO7204239 (also called GYM329)
What this could lead to: If it works, this could point toward a new treatment that helps control blood sugar and improve muscle function in people with type 2 diabetes.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so results may not apply to everyone. The drug may not improve insulin sensitivity or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Profil Institut für Stoffwechselforschung

Homburg, Saarland, 66421, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.